Old Web
English
Sign In
Acemap
>
authorDetail
>
Ulrich Elsasser
Ulrich Elsasser
Boehringer Ingelheim
Medicine
Type 2 diabetes
in patient
Empagliflozin
Internal medicine
4
Papers
25
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
2020
The Lancet Diabetes & Endocrinology
Darren K. McGuire
Bernard Zinman
Silvio E. Inzucchi
Christoph Wanner
David Fitchett
Stefan D. Anker
Stuart J. Pocock
Stefan Kaspers
Jyothis T. George
Maximilian von Eynatten
Odd Erik Johansen
Waheed Jamal
Michaela Mattheus
Ulrich Elsasser
Stefan Hantel
Søren S Lund
Show All
Source
Cite
Save
Citations (7)
P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease
2019
European Heart Journal
Darren K. McGuire
Bernard Zinman
Silvio E. Inzucchi
Stefan D. Anker
Christoph Wanner
Stefan Kaspers
M. von Eynatten
Odd Erik Johansen
Ulrich Elsasser
Stuart J. Pocock
David Fitchett
W Jamal
Stefan Hantel
S. Lund
Show All
Source
Cite
Save
Citations (1)
Asthma impacts on workplace productivity in employed patients who are symptomatic despite background therapy: a multinational survey
2019
Journal of Asthma and Allergy
Kevin Gruffydd-Jones
Mike Thomas
Miguel Roman Rodriguez
Antonio Infantino
J. Mark FitzGerald
Ian D. Pavord
Jennifer M. Haddon
Ulrich Elsasser
Christian Vogelberg
Show All
Source
Cite
Save
Citations (12)
Slope of change in HbA1c from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes
2018
Ralph A. DeFronzo
Ele Ferrannini
Guntram Schernthaner
Stefan Hantel
Ulrich Elsasser
Christopher Lee
Thomas Hach
Søren S Lund
Show All
Source
Cite
Save
Citations (5)
1